

# Syngene

Ref: Syn/CS/SE/RPT/2020-21/Nov/76

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 & 3,  
Bommasandra Industrial Area, IV Phase,  
Jigani Link Road, Bengaluru 560099,  
Karnataka, India.  
T +91 80 6891 8000  
F +91 80 6891 8808  
CIN: L85110KA1993PLC01493  
[www.syngeneintl.com](http://www.syngeneintl.com)

November 19,2020

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

Dear Sir/Madam,

**Subject: Submission of Disclosure on Related Parties Transactions**

Pursuant to Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions on Consolidated basis for the half-year ended September 30, 2020, drawn in accordance with the applicable Accounting Standards.

The above-mentioned disclosure will also be available on website of the Company [www.syngeneintl.com](http://www.syngeneintl.com).

Kindly take the above information on record.

Thanking You,

Yours faithfully,  
For **SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
Priyadarshini Mahapatra  
**Company Secretary and Compliance Officer**

## DISCLOSURE OF RELATED PARTY TRANSACTIONS – ON CONSOLIDATED BASIS

In pursuance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

### A. List of key management personnel

Sl No	Name of the related party	Relationship
(a)	Kiran Mazumdar Shaw	Chairperson (w.e.f. 1 April 2020)
	Kiran Mazumdar Shaw	Chairperson and Managing Director (till 31 March 2020)
(b)	John Shaw	Non-executive director
(c)	Jonathan Hunt	Managing Director and Chief Executive Officer (w.e.f. 1 April 2020)
	Jonathan Hunt	Director and Chief Executive Officer (till 31 March 2020)
(d)	Catherine Rosenberg	Non-executive director
(e)	Bala S. Manian	Independent director (till 15 July 2020)
(f)	Paul Blackburn	Independent director
(g)	Vijay Kuchroo	Independent director
(h)	Vinita Bali	Independent director
(i)	Sharmila Abhay Karve	Independent director (w.e.f. 1 August 2019)
(j)	Carl Decicco	Independent director (w.e.f. 1 October 2019)
(k)	Russell Walls	Independent director (till 24 July 2019)
(l)	Suresh Talwar	Independent director (till 24 July 2019)
(m)	Sibaji Biswas	Chief Financial officer (w.e.f. 18 December 2019)
(n)	Priyadarshini Mahapatra	Company Secretary (w.e.f. 24 July 2019)
(o)	M B Chinappa	Chief Financial officer (till 17 December 2019)
(p)	Mayank Verma	Company Secretary (till 24 May 2019)

## B. OTHER RELATED PARTIES

SI No	Name of the related party	Relationship
(a)	Biocon Limited	Holding Company
(b)	Biocon Sdn. Bhd., Malaysia	Fellow subsidiary
(c)	Biocon Pharma Limited	Fellow subsidiary
(d)	Biocon SA, Switzerland	Fellow subsidiary
(e)	Biocon Biologics UK Limited (formerly known as Biocon Biologics Limited)	Fellow subsidiary
(f)	Biocon Pharma Inc, USA	Fellow subsidiary
(g)	Biocon FZ LLC, UAE	Fellow subsidiary
(h)	Biocon Biologics Limited (formerly known as Biocon Biologics India Limited)	Fellow subsidiary
(i)	Biocon Biologics Healthcare Sdn. Bhd, Malaysia (formerly known as Biocon Healthcare Sdn. Bhd, Malaysia)	Fellow subsidiary
(j)	Biocon Academy	Fellow subsidiary
(k)	Bicara Therapeutics Inc	Fellow subsidiary
(l)	Biocon Pharma UK Limited	Fellow subsidiary
(m)	Biocon Pharma Ireland Limited	Fellow subsidiary
(n)	Biocon Biosphere Limited	Fellow subsidiary
(o)	Biocon Biologics Inc	Fellow subsidiary
(p)	Biocon Biologics Do Brasil Ltda	Fellow subsidiary
(q)	Biocon Foundation	Trust in which director is a trustee
(r)	Narayana Hrudayalaya Limited	Enterprise in which a director of the Company is a member of board of directors
(s)	Jeeves	Enterprise in which relative to a director of the Company is proprietor
(t)	Immuneel Therapeutics Private Limited	Enterprise in which a director of the Company is a member of board of directors

## II. TRANSACTIONS WITH RELATED PARTY

(Amount in Indian Rupees Million)

Particulars	Transaction/ Balances	Half year ended 30 Sep 2020	Half year ended 30 Sep 2019	Year ended 31 March 2020
Key management personnel	Salary and perquisites [refer note (i) and (ii) below]	53	66	115
	Sitting fees and commission	11	12	23
	Outstanding as at the period/ year end - Trade and other payables	10	11	5
Holding company	Rent	29	29	63
	Power and facility charges [refer note (iii) below]	57	226	360
	Purchase of goods	- *	2	2
	Other expenses reimbursed to	30	24	79
	Purchase of assets	-	-	31
	Sale of services	37	38	80
	Supply of power services	2	-	-
	Other expenses reimbursed from	1	-	-
	Final dividend paid	-	140	140
	Outstanding as at the period/ year end - Trade and other payables	39	290	217
	- Rent deposits	23	23	23
	- Trade and other receivables	48	28	34
Guarantee given to Central Excise Department	148	148	148	
Fellow subsidiaries	Sale of services	108	178	392
	Rent and facility services	124	116	233
	Supply of power and utility services	41	-	-
	Other expenses reimbursed from	1	-	-
	Purchase of assets	-	-	56
	Purchase of goods	-	- *	- *
	Outstanding as at the period/ year end - Trade and other payables	24	- *	51
	- Trade and other receivables	273	324	328
Other related parties	Sale of services	1	- *	1
	Health services availed	1	2	4
	Contribution towards CSR	-	10	74
	Staff welfare expenses	1	2	4
	Investment in compulsorily convertible debentures	-	-	100
	Outstanding as at the period/year end - Trade and other payables	-	-	-
	- Trade and other receivables	- *	-	-

\* Less than Rs. 0.5 million.

**Notes:**

(i) The remuneration to the key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are determined on an actuarial basis for the Company as a whole.

(ii) Share based compensation expense allocable to key management personnel is Rs. 51 (30 Sep 2019 :Rs. 19, 31 March 2020: Rs. 80) for the half year ended 30 Sep 2020, which is not included in the remuneration disclosed above.

(iii) The Company has entered into an arrangement for lease of land on lease basis and a service agreement with 'Biocon SEZ Developer' of Biocon Limited for availing certain facilities and services. The facility charges of Rs. 55 (30 Sep 2019: Rs. 64; 31 March 2020: Rs.115) and power charges (including other charges) of Rs. 2 (30 Sep 2019: Rs. 162; 31 March 2020: Rs. 245) have been charged by Biocon Limited for the half year ended 30 Sep 2020.

(iv) The above disclosures include related parties as per IND-As 24 on "Related Party Disclosures" and Companies Act, 2013.

(v) All transactions with these related parties are priced on an arm's length basis and none of the balances are secured.

(Amount in Indian Rupees Million)